Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Stock Information | RedChip

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Listen to this Section


$12.08
-0.3900 ( -3.13% ) 61.6K

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Market Data


Open


$12.08

Previous close


$12.47

Volume


61.6K

Market cap


$213.08M

Day range


$12.07 - $12.57

52 week range


$7.12 - $17.30

Insider Ownership Transactions

Total Amount Purchased: -1,154,301.00 | $ -13,943,956.08

Date Type Amount Purchased Purchaser
2024-03-01 Sale -93750.00 Furey Raymond J.
2024-02-06 Sale -5601.00 Santos David A
2024-02-06 Sale -5601.00 Schorno Dean L
2024-02-06 Sale -22349.00 RODRIGUEZ RAUL R
2024-01-25 Sale -209000.00 Furey Raymond J.
2024-01-25 Sale -400000.00 RODRIGUEZ RAUL R
2024-01-25 Sale -209000.00 Santos David A
2024-01-25 Sale -209000.00 Schorno Dean L

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 May 29, 2024
8-k 8K-related 15 May 07, 2024
10-q Quarterly Reports 80 May 07, 2024
8-k 8K-related 13 Apr 12, 2024
def Proxies and info statements 41 Apr 10, 2024
ars Annual reports 1 Apr 10, 2024
pre Proxies and info statements 39 Mar 29, 2024
4 Insider transactions 1 Mar 29, 2024
3 Insider transactions 2 Mar 29, 2024
10-k Annual reports 101 Mar 05, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.